Ra Capital Management, L.P. Purchases 1,341,420 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock
Ra Capital Management, L.P. Purchases 1,341,420 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Rating) major shareholder Ra Capital Management, L.P. purchased 1,341,420 shares of the firm's stock in a transaction on Friday, December 16th. The stock was bought at an average cost of $5.42 per share, with a total value of $7,270,496.40. Following the completion of the acquisition, the insider now directly owns 9,403,049 shares of the company's stock, valued at approximately $50,964,525.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
支点治疗公司(纳斯达克代码：FULC-GET Rating)的大股东Ra Capital Management，L.P.在12月16日星期五的一项交易中购买了该公司1,341,420股股票。这只股票的平均价格为每股5.42美元，总价值为7,270,496.40美元。收购完成后，该内部人士现在直接拥有该公司9,403,049股股票，价值约50,964,525.58美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可以通过这个环节。持有公司10%以上股份的大股东被要求披露他们与美国证券交易委员会的交易。
Ra Capital Management, L.P. also recently made the following trade(s):
Ra Capital Management，L.P.最近还进行了以下交易：
- On Wednesday, December 14th, Ra Capital Management, L.P. purchased 824,600 shares of Fulcrum Therapeutics stock. The stock was bought at an average cost of $5.46 per share, with a total value of $4,502,316.00.
- 12月14日，星期三，Ra Capital Management，L.P.购买了824,600股支点治疗公司的股票。这只股票的平均价格为每股5.46美元，总价值为4,502,316.00美元。
Fulcrum Therapeutics Price Performance
支点治疗药物性价比
NASDAQ FULC traded down $0.13 during mid-day trading on Friday, hitting $5.35. The stock had a trading volume of 2,932,283 shares, compared to its average volume of 575,955. The firm's 50 day moving average is $6.42 and its 200 day moving average is $6.70. Fulcrum Therapeutics, Inc. has a twelve month low of $3.21 and a twelve month high of $24.79. The stock has a market capitalization of $278.47 million, a price-to-earnings ratio of -2.14 and a beta of 1.96.
纳斯达克周五午盘下跌0.13美元，触及5.35美元。该股成交量为2932,283股，而其平均成交量为575,955股。该公司的50日移动均线切入位在6.42美元，200日移动均线切入位在6.70美元。支点治疗公司的12个月低点为3.21美元，12个月高位为24.79美元。该股市值为2.7847亿美元，市盈率为-2.14倍，贝塔系数为1.96。
Analysts Set New Price Targets
分析师设定新的价格目标
Institutional Inflows and Outflows
机构资金流入和流出
Hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. purchased a new stake in Fulcrum Therapeutics in the 3rd quarter valued at $56,630,000. FMR LLC grew its holdings in Fulcrum Therapeutics by 0.5% in the 2nd quarter. FMR LLC now owns 6,127,231 shares of the company's stock valued at $30,023,000 after buying an additional 30,753 shares in the last quarter. RTW Investments LP grew its holdings in Fulcrum Therapeutics by 0.6% in the 3rd quarter. RTW Investments LP now owns 3,985,910 shares of the company's stock valued at $32,246,000 after buying an additional 24,716 shares in the last quarter. BlackRock Inc. grew its holdings in Fulcrum Therapeutics by 4.4% in the 3rd quarter. BlackRock Inc. now owns 2,772,344 shares of the company's stock valued at $22,428,000 after buying an additional 117,966 shares in the last quarter. Finally, Suvretta Capital Management LLC grew its holdings in Fulcrum Therapeutics by 10.0% in the 1st quarter. Suvretta Capital Management LLC now owns 2,613,412 shares of the company's stock valued at $61,807,000 after buying an additional 237,841 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.
对冲基金最近增持或减持了该公司的股份。RA Capital Management L.P.在第三季度购买了Fulcrum Treateutics的新股份，价值56,630,000美元。FMR LLC在第二季度增持了Fulcrum Treeutics 0.5%的股份。FMR LLC现在拥有6,127,231股该公司的股票，价值30,023,000美元，上个季度又购买了30,753股。RTW Investments LP在第三季度增持了Fulcrum Treeutics 0.6%的股份。RTW Investments LP现在拥有3985,910股该公司股票，价值32,246,000美元，上个季度又购买了24,716股。贝莱德股份有限公司在第三季度增持了支点治疗公司4.4%的股份。贝莱德股份有限公司现在持有该公司2,772,344股股票，价值22,428,000美元，该公司在上个季度又购买了117,966股。最后，Suvretta Capital Management LLC在第一季度将其在Fulcrum Treeutics的持股增加了10.0%。Suvretta Capital Management LLC现在拥有2,613,412股该公司股票，价值61,807,000美元，上个季度又购买了237,841股。96.96%的股票由机构投资者和对冲基金持有。
Fulcrum Therapeutics Company Profile
支点治疗公司简介
(Get Rating)
(获取评级)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
FULCRUM治疗公司是一家临床阶段的生物制药公司，专注于开发产品，以改善美国高度未得到满足的医疗需求领域的遗传性疾病患者的生活。它的候选产品是losmapimod，一种用于治疗面肩肩周肌营养不良的小分子；以及FTX-6058，一种研究中的口服胎儿血红蛋白诱导剂，用于治疗镰状细胞疾病和其他血红蛋白疾病，包括β-地中海贫血。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Fulcrum Therapeutics (FULC)
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- 免费获取StockNews.com关于Fulcrum治疗(FULC)的研究报告
- 哪两家蓝筹科技公司提高了他们的指引？
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
- 拖拉机库存能否突破杯柄收购点？
- 现在不是购买Lennar的时候，但时机即将到来
- 马伦汽车公司改变游戏规则的消息
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《支点治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Fulcrum治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。